[1]
Muto J, Shirabe K, Yoshizumi T, et al. The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. Anticancer Res 2014; 34(10): 5313-20.
[2]
Tang CM, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol 2013; 28(3): 401-5.
[3]
He L, Xu J, Chen L, Li L. Apelin/APJ signaling in hypoxia-related
diseases. Clin Chim Acta 2015; 451(Pt B): 191-8.
[4]
Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014; 110(3): 398-403.
[5]
Lee SH, Jeong D, Han YS, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 2015; 89(1): 1-8.
[6]
Folino A, Montarolo PG, Samaja M, Rastaldo R. Effects of apelin on the cardiovascular system. Heart Fail Rev 2015; 20(4): 505-18.
[7]
Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 2010; 62(3): 331-42.
[8]
Cox CM, D’Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296(1): 177-89.
[9]
Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005; 126(3): 233-40.
[10]
Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004; 18(15): 1909-11.
[11]
Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325(2): 395-400.
[12]
Kidoya H, Kunii N, Naito H, et al. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy. Oncogene 2012; 31(27): 3254-64.
[13]
Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007; 26(55): 7692-9.
[14]
Lacquaniti A, Altavilla G, Picone A, et al. Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med 2015; 15(1): 97-105.
[15]
Berta J, Kenessey I, Dobos J, et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol 2010; 5(8): 1120-9.
[16]
Heo K, Kim YH, Sung HJ, et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol 2012; 48(6): 500-6.
[17]
Sheikh AY, Chun HJ, Glassford AJ, et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 2008; 294(1): H88-98.
[18]
Han S, Wang G, Qi X, Lee HM, Englander EW, Greeley GH Jr. A possible role for hypoxia-induced apelin expression in enteric cell proliferation. Am J Physiol Regul Integr Comp Physiol 2008; 294(6): R1832-9.
[19]
Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008; 103(4): 432-40.
[20]
Li L, Li L, Zhang Z, Jiang Z. Hypoxia promotes bone marrow-derived mesenchymal stem cell proliferation through apelin/APJ/autophagy pathway. Acta Biochim Biophys Sin 2015; 47(5): 362-7.
[21]
Kong HL, Li ZQ, Zhao SM, et al. Apelin-APJ effects of ginsenoside-Rb1 depending on hypoxia-induced factor 1α in hypoxia neonatal cardiomyocytes. Chin J Integr Med 2015; 21(2): 139-46.
[22]
Geiger K, Muendlein A, Stark N, et al. Hypoxia induces apelin expression in human adipocytes. Horm Metab Res 2011; 43(6): 380-5.
[23]
Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O’Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146(1): 231-6.
[24]
Maloney PR, Khan P, Hedrick M, et al. Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML2 21) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett 2012; 22(21): 6656-60.
[25]
Zhou N, Fang J, Acheampong E, Mukhtar M, Pomerantz RJ. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology 2003; 312(1): 196-203.
[26]
Lu Q, Jiang YR, Qian J, Tao Y. Apelin-13 regulates proliferation, migration and survival of retinal Müller cells under hypoxia. Diabetes Res Clin Pract 2013; 99(2): 158-67.
